Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Melanoma 24Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Carcinoma, Renal Cell 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Neuroblastoma 4Neoplasms 4Lymphoma 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Esophageal Neoplasms 3Colonic Neoplasms 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Oxaliplatin 16Irinotecan 12Fluorouracil 12Leucovorin 10Bevacizumab 8pembrolizumab 7Cetuximab 7Capecitabine 7Nivolumab 5Gemcitabine 5Cyclophosphamide 5fludarabine 4aldesleukin 4Panitumumab 4Folfox protocol 4oblimersen 3Interleukin-2 3selpercatinib 2poly ICLC 2labetuzumab 2dehydroftorafur 2conatumumab 2cemiplimab 2bintrafusp alfa protein, human 2Tomography, X-Ray Computed 2Specimen Handling 2Receptor Protein-Tyrosine Kinases 2Radiotherapy 2Levoleucovorin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Colonic Neoplasms × Interleukin-2 × Clear all
NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT04426669 2026-02-23

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Intima Bioscience, Inc.

Phase 1/2 Completed
23 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06530303 2024-11-05

BAH248

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡